Cost-utility analysis of dorzagliatin combined with metformin in the treatment of type 2 diabetes mellitus patients with poor glycemic control with metformin

GAO Ning; FENG Bing; GAO Shengnan; GUO Shan; NIU Mengna; LIU Guoqiang

doi:10.6039/j.issn.1001-0408.2024.06.15

您当前的位置：

首页 >

文章列表页 >

Cost-utility analysis of dorzagliatin combined with metformin in the treatment of type 2 diabetes mellitus patients with poor glycemic control with metformin

更新时间：2024-04-09

- Cost-utility analysis of dorzagliatin combined with metformin in the treatment of type 2 diabetes mellitus patients with poor glycemic control with metformin
- ZHONGGUO YAOFANG Vol. 35, Issue 6, Pages: 724-728(2024)
- 作者机构：
  
  1.河北医科大学第三医院临床药学部，石家庄　050051
  2.河北省药物与卫生技术综合评估学会，石家庄　050051
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2024.06.15
  CLC： R956
- Published：30 March 2024，
  
  Received：14 September 2023，
  
  Revised：19 February 2024，
扫描看全文
高宁,冯冰,高胜男等.多格列艾汀联用治疗二甲双胍失效2型糖尿病患者的成本-效用分析 ^Δ[J].中国药房,2024,35(06):724-728.

GAO Ning,FENG Bing,GAO Shengnan,et al.Cost-utility analysis of dorzagliatin combined with metformin in the treatment of type 2 diabetes mellitus patients with poor glycemic control with metformin[J].ZHONGGUO YAOFANG,2024,35(06):724-728.
高宁,冯冰,高胜男等.多格列艾汀联用治疗二甲双胍失效2型糖尿病患者的成本-效用分析 ^Δ[J].中国药房,2024,35(06):724-728. DOI： 10.6039/j.issn.1001-0408.2024.06.15.

GAO Ning,FENG Bing,GAO Shengnan,et al.Cost-utility analysis of dorzagliatin combined with metformin in the treatment of type 2 diabetes mellitus patients with poor glycemic control with metformin[J].ZHONGGUO YAOFANG,2024,35(06):724-728. DOI： 10.6039/j.issn.1001-0408.2024.06.15.

摘要

目的

对多格列艾汀联用治疗二甲双胍失效的2型糖尿病（T2DM）进行经济学评价。

方法

基于多格列艾汀联合二甲双胍治疗T2DM的Ⅲ期随机对照试验研究，建立Markov模型，从我国卫生体系角度出发，通过队列模拟预测各方案长期的成本与效用。以质量调整生命年（QALYs）为健康产出指标，以2022年人均国内生产总值（GDP）的3倍作为意愿支付阈值（WTP），分析增量成本-效果比（ICER），并进行敏感性分析和情境分析。

结果

模拟30年疾病进展后，与单用二甲双胍相比，多格列艾汀联合二甲双胍治疗可使有并发症的转移概率降低15.1%，死亡的转移概率降低8.5%，累计效用改善0.62 QALYs，ICER为235 260.30元/QALY，小于WTP，增加的成本可接受。单因素敏感性分析结果表明，干预组无并发症成本、糖尿病无并发症效用值、糖尿病有并发症效用值对ICER影响较大。概率敏感性分析结果显示，多格列艾汀联合二甲双胍治疗方案具有经济性的概率为68.8%。情境分析结果表明，随着多格列艾汀价格的下降，联合治疗方案具有经济性的优势更明显。

结论

对于单用二甲双胍血糖控制不佳的T2DM患者，多格列艾汀联合二甲双胍治疗方案具有长期成本-效用优势，但具有经济性的概率仅近70%。

Abstract

OBJECTIVE

To evaluate the cost-effectiveness of dorzagliatin combined with metformin in the treatment of type 2 diabetes mellitus （T2DM） patients with poor glycemic control with metformin.

METHODS

A Markov model was established based on a phase Ⅲ randomized controlled trial study of dorzagliatin combined with metformin in the treatment of T2DM. From the perspective of the Chinese health system， cohort simulation was used to predict the long-term cost-utility of each strategy. Using the quality-adjusted life years （QALYs） as the health output indicator， three times the 2022 gross domestic product （GDP） per capita as the willingness-to-pay threshold （WTP）， the incremental cost-effectiveness ratio （ICER） was analyzed， then sensitivity analyses and scenario analysis were also performed.

RESULTS

After simulating 30 years of disease progression， compared with metformin， dorzagliatin combined with metformin reduced the probability of metastasis with complications by 15.1%， and the probability of death by 8.5%， improved cumulative utility by 0.62 QALYs， with an ICER of 235 260.30 yuan/QALY， which was less than the WTP， and an acceptable increase in cost. The results of the single-factor sensitivity analysis showed that the ICER value was greatly affected by the cost of no complications in the intervention group， the utility value of diabetes without complications， and the utility value of diabetes with complications. Probabilistic sensitivity analysis showed that the probability of combination therapy being cost-effective was 68.8%. The results of scenario analysis showed that with the decline in the price of dorzagliatin， the combination therapy had more obvious economic advantages.

CONCLUSIONS

For T2DM patients with poor glycemic control with metformin alone， the combination of dorzagliatin and metformin has long-term cost-utility advantages， but the economic probability is only close to 70%.

关键词

多格列艾汀二甲双胍2型糖尿病Markov模型成本-效用分析

Keywords

metformintype 2 diabetes mellitusMarkov modelcost-utility analysis

references

ALMIGBAL T H，ALZARAH S A，ALJANOUBI F A，et al. Clinical inertia in the management of type 2 diabetes mellitus：a systematic review[J]. Medicina，2023，59（1）：182.

中华医学会糖尿病学分会. 中国2型糖尿病防治指南：2020年版：上[J]. 中国实用内科杂志，2021，41（8）：668-695.

Chinese Diabetes Society. Guideline for the prevention and treatment of type 2 diabetes mellitus in China：2020 edition：part 1[J]. Chin J Pract Intern Med，2021，41（8）：668-695.

吴起润，李兰芳，曾姣娥. 葡萄糖激酶激活剂及其新药多格列艾汀在2型糖尿病中的研究进展[J]. 糖尿病新世界，2022，25（19）：195-198.

WU Q R，LI L F，ZENG J E. Research progress of glucokinase activator and its new drug dorzagliatin in type 2 diabetes mellitus[J]. Diabetes N World，2022，25（19）：195-198.

赵紫楠，史琛，胡欣，等.葡萄糖激酶激活剂多格列艾汀药学专家共识[J].中国医院药学杂志，2024，44（3）：245-250.

ZHAO Z N，SHI C，HU X，et al. Expert consensus on the pharmacy of glucokinase agonist dorzagliatin[J]. Chin J Hosp Pharm，2024，44（3）：245-250.

YANG W Y，ZHU D L，GAN S L，et al. Dorzagliatin add-on therapy to metformin in patients with type 2 diabetes：a randomized，double-blind，placebo-controlled phase 3 trial[J]. Nat Med，2022，28（5）：974-981.

刘海娇，王雅洁，吴玉霞，等. 2型糖尿病治疗药物经济学评价模型的分析研究[J]. 中国药房，2020，31（19）：2392-2398.

LIU H J，WANG Y J，WU Y X，et al. Analysis study of pharmacoeconomic evaluation model of therapy for type 2 diabetes mellitus[J]. China Pharm，2020，31（19）：2392-2398.

熊朝刚，朱玉蓉，李颖，等. 恩格列净与二甲双胍联合治疗2型糖尿病的药物经济学评价[J]. 中国医院药学杂志，2021，41（9）：880-885.

XIONG C G，ZHU Y R，LI Y，et al. Pharmacoeconomic evaluations of empagliflozin plus metformin in the treatment of type 2 diabetes mellitus[J]. Chin J Hosp Pharm，2021，41（9）：880-885.

宋安民. 两种方案治疗2型糖尿病的效价比分析[J]. 糖尿病新世界，2016，19（6）：67-68.

SONG A M. Cost-effectiveness analysis of two therapeutic schemes in the treatment of type 2 diabetes[J]. Diabetes N World，2016，19（6）：67-68.

袁虹. 2型糖尿病并发症对患者年治疗费用负担的影响分析[J]. 中国医药指南，2015，13（14）：21-22.

YUAN H. Analysis of complications of type 2 diabetes in patients with treatment costs[J]. Guide China Med，2015，13（14）：21-22.

REDEKOP W K，KOOPMANSCHAP M A，STOLK R P，et al. Health-related quality of life and treatment satisfaction in Dutch patients with type 2 diabetes[J]. Diabetes Care，2002，25（3）：458-463.

TURNER R C，HOLMAN R R，STRATTON I M，et al. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes：UKPDS 34[J]. Lancet，1998，352（9131）：854-865.

JrCLARK C M. The burden of chronic hyperglycemia[J]. Diabetes Care，1998，21（Suppl 3）：C32-C34.

周挺，马爱霞，付露阳. 药物经济学评价Markov模型中转移概率计算的探讨[J]. 中国卫生经济，2017，36（12）：40-42.

ZHOU T，MA A X，FU L Y. Discussion on the calculation of Markov model transition probability in pharmacoecono-mics evaluation[J]. Chin Health Econ，2017，36（12）：40-42.

刘国恩. 中国药物经济学评价指南2020[M]. 北京：中国市场出版社，2020：27-28，45-47.

LIU G E. China guidelines for pharmacoeconomic evaluations 2020[M]. Beijing：China Market Press，2020：27-28，45-47.

BEAUDET A，CLEGG J，THURESSON P O，et al. Review of utility values for economic modeling in type 2 diabetes[J]. Value Health，2014，17（4）：462-470.

ZENG J E，GAN S L，MI N R，et al. Diabetes remission in drug-naïve patients with type 2 diabetes after dorzagliatin treatment：a prospective cohort study[J]. Diabetes Obes Metab，2023，25（10）：2878-2887.

陈洁，龙恩武，胡明. 糖尿病治疗指标的意愿支付调查及影响因素分析[J]. 中国药房，2016，27（18）：2456-2460.

CHEN J，LONG E W，HU M. Survey of willingness to pay of treatment index in diabetes and influential factors analysis[J]. China Pharm，2016，27（18）：2456-2460.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Cost-utility analysis of trastuzumab deruxtecan versus trastuzumab emtansine in the second-line treatment for HER2-positive metastatic breast cancer

Pharmacoeconomic evaluation of clopidogrel versus aspirin for secondary prevention of ischemic stroke

Cost-utility analysis of tislelizumab monotherapy for second-line treatment of advanced or metastatic esophageal squamous cell carcinoma

Introduction of measurement methods of health utility for cancer patients

Cost-utility analysis of denosumab and teriparatide in the treatment of postmenopausal osteoporosis in Chinese women

Related Author

HOU Yanhong

WU Fang

WU Yanan

LANG Yitian

ZHU Chunli

TAO Wenqi

LIAO Yahui

ZHANG Chi

Related Institution

School of International Pharmaceutical Business， China Pharmaceutical University

Dept. of Pharmacy， Huangpu Branch， Shanghai Ninth People’s Hospital， Shanghai Jiaotong University School of Medicine

Dept. of Pharmacy， Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine

Clinical Research Center， Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine

Clinical Pharmaceutics Room， the First Affiliated Hospital of Xi’an Medical University

Address：8/F,129 Daping Main Street,Yuzhong District,Chongqing 400042,P.R.China
Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号公网安备50010302001817
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰